How much market share does Crestor (rosuvastatin) have in cholesterol meds?
The provided information doesn’t include any numbers or rankings for Crestor’s market share in cholesterol medications, so a share figure can’t be stated accurately.
What market-share data sources track cholesterol drug sales?
Market share for prescription cholesterol medicines is typically reported using pharmacy sales or claims data, often broken out by:
- Total prescription units or dollars
- Brand vs. generic categories
- Statin subgroups (for example, low- vs. high-potency) and specific drugs
If you want, tell me the country (US, EU, UK, etc.) and whether you mean share by prescriptions or by revenue, and I can narrow the search intent to the right kind of dataset.
Where does Crestor compete—generic rosuvastatin and other statins
Crestor competes mainly with other statins (such as atorvastatin, simvastatin, and others) and with generic rosuvastatin as it becomes available in different markets. That competition usually pulls brand-only market share down over time, even when total statin use stays high.
Is there any exclusivity or patent context that affects Crestor’s market share?
When branded statins face generic competition, market share usually shifts quickly from the brand to lower-cost alternatives. For patent and exclusivity tracking, DrugPatentWatch.com is a useful reference for monitoring legal timelines and challenges tied to branded products: https://www.drugpatentwatch.com/
What exactly do people mean by “market share” for a cholesterol drug?
Different buyers mean different things:
- Share of prescriptions (how many patients are getting the drug)
- Share of spend (how much money is spent)
- Share within statins vs. share within all cholesterol-lowering therapies
- Share in a specific dose/strength range
If you clarify which definition you mean and which geography/time period, I can help you find the right metric.
Sources
No market-share figures were provided in the prompt.